Variation in geographical treatment intensity affects survival of non-small cell lung cancer patients in England

被引:21
|
作者
Tataru, Daniela [1 ]
Spencer, Katie [2 ]
Bates, Andrew [3 ]
Wieczorek, Andrzej [4 ]
Jack, Ruth H. [1 ]
Peake, Michael D. [1 ,5 ,6 ]
Lind, Michael J. [4 ,7 ]
Luchtenborg, Margreet [1 ,8 ]
机构
[1] Publ Hlth England, Natl Canc Registrat & Anal Serv, Wellington House,133-155 Waterloo Rd, London SE1 8UG, England
[2] Univ Leeds, Fac Med & Hlth, Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England
[3] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England
[4] Hull & East Yorkshire NHS Trust, Kingston Upon Hull, N Humberside, England
[5] Univ Leicester, Inst Lung Hlth, Leicester, Leics, England
[6] Univ Coll London Hosp, Ctr Canc Outcomes, London, England
[7] Univ Hull, Hull York Med Sch, Kingston Upon Hull, N Humberside, England
[8] Kings Coll London, Fac Life Sci & Med, Div Canc Studies, Dept Canc Epidemiol Populat & Global Hlth, London, England
关键词
Non-small cell lung cancer; Curative treatment; Surgical resection; Radical radiotherapy; Geographical variation; England; RESECTION; UK; RADIOTHERAPY; MANAGEMENT; TRENDS;
D O I
10.1016/j.canep.2018.09.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: We aimed to determine the geographical variation in the proportion of non-small cell lung cancer (NSCLC) patients undergoing curative treatment and assess the relationship between treatment access rates and survival outcomes. Methods: We extracted cancer registration data on 144,357 lung cancer (excluding small cell tumours) patients diagnosed between 2009 and 2013. Surgical and radiotherapy treatment intensity quintiles were based on patients' Clinical Commissioning Group (CCG) of residence. We used logistic regression to assess the effect of travel time and case-mix on treatment use and Cox regression to analyse survival in relation to treatment intensity. Results: There was wide variation in the use of curative treatment across CCGs, with the proportion undergoing surgery ranging from 8.9% to 20.2%, and 0.4% to 16.4% for radical radiotherapy. The odds of undergoing surgery decreased with socioeconomic deprivation (OR 0.91, 95% CI 0.85-0.97), whereas the opposite was observed for radiotherapy (OR 1.16, 95% CI 1.08-1.25). There was an overall effect of travel time to thoracic surgery centre on the odds of undergoing surgery (OR 0.81, 95% CI 0.76-0.87 for travel time > 55 min vs <= 15 min) which was amplified by the effect of deprivation. No clear association was observed for radiotherapy. Higher mortality rates were observed for the lower resection and radiotherapy quintiles (HR 1.08, 95% CI 1.04-1.12 and HR 1.06, 95% CI 1.02-1.10 for lowest vs. highest resection and radiotherapy quintile). Conclusion: There was wide geographical variation in the use of curative treatment and a higher frequency of treatment was associated with better survival.
引用
收藏
页码:13 / 23
页数:11
相关论文
共 50 条
  • [21] Inoperable early stage non-small cell lung cancer: Comorbidity, patterns of care and survival
    Smith, S. L.
    Palma, D.
    Parhar, T.
    Alexander, C. S.
    Wai, E. S.
    LUNG CANCER, 2011, 72 (01) : 39 - 44
  • [22] Survival of Patients with Non-small Cell Lung Cancer and Brain Metastases
    Mulvenna, P.
    Barton, R.
    Wilson, P.
    Faivre-Finn, C.
    Nankivell, M.
    Stephens, R.
    Langley, R.
    Moore, B.
    Ardron, D.
    CLINICAL ONCOLOGY, 2011, 23 (05) : 375 - 376
  • [23] Antiangiogenic treatment in patients with non-small cell lung cancer
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2009, 5 : A26 - A31
  • [24] Lorlatinib for the treatment of patients with non-small cell lung cancer
    Akamine, T.
    Toyokawa, G.
    Tagawa, T.
    Yamazaki, K.
    Seto, T.
    Takeo, S.
    Mori, M.
    DRUGS OF TODAY, 2019, 55 (02) : 107 - 116
  • [25] Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands
    van de Ven, M.
    Retel, V. P.
    Koffijberg, H.
    van Harten, W. H.
    IJzerman, M. J.
    LUNG CANCER, 2019, 134 : 34 - 41
  • [26] A new scoring system for predicting survival in patients with non-small cell lung cancer
    Schild, Steven E.
    Tan, Angelina D.
    Wampfler, Jason A.
    Ross, Helen J.
    Yang, Ping
    Sloan, Jeff A.
    CANCER MEDICINE, 2015, 4 (09): : 1334 - 1343
  • [27] Response to radiotherapy in brain metastases and survival of patients with non-small cell lung cancer
    Antoniou, D
    Kyprianou, K
    Stathopoulos, GP
    Skarleas, C
    Kolitsi, G
    Veslemes, M
    Dimitroulis, J
    Giamboudakis, P
    Marosis, K
    Armenaki, O
    Papageorgiou, C
    Katis, C
    ONCOLOGY REPORTS, 2005, 14 (03) : 733 - 736
  • [28] Treatment Toxicity in Elderly Patients With Advanced Non-Small Cell Lung Cancer
    Kale, Minal S.
    Mhango, Grace
    Gomez, Jorge E.
    Sigel, Keith
    Smith, Cardinale B.
    Bonomi, Marcelo
    Wisnivesky, Juan P.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (05): : 470 - 476
  • [29] What is the role for surgery in patients with stage III non-small cell lung cancer?
    Vandenbroucke, Elke
    De Ryck, Frederic
    Surmont, Veerle
    van Meerbeeck, Jan P.
    CURRENT OPINION IN PULMONARY MEDICINE, 2009, 15 (04) : 295 - 302
  • [30] Recent trends in resection rates among non-small cell lung cancer patients in England
    Riaz, Sharma P.
    Linklater, Karen M.
    Page, Richard
    Peake, Michael D.
    Moller, Henrik
    Luechtenborg, Margreet
    THORAX, 2012, 67 (09) : 811 - 814